SkinBioTherapeutics - Director Dealing

RNS Number : 6641H

SkinBioTherapeutics PLC

04 December 2020

SkinBioTherapeutics plc

Director Dealing

The Company was informed today that on 4 December 2020 the CFO of the Company, Doug Quinn and persons closely associated with him, sold 253,190 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 16 pence per Ordinary Share and then repurchased, into their ISAs, 248,220 Ordinary Shares at a price of 16.02 pence per Ordinary Share to facilitate ISA transfers.

For more information please contact:

SkinBioTherapeutics plc	Tel: +44 (0) 161 468 2760
Stuart Ashman, CEO Doug Quinn, CFO
Cenkos Securities plc (Nominated Adviser & Broker)	Tel: +44 (0) 20 7397 8900
Giles Balleny, Max Gould (Corporate Finance) Michael Johnson (Sales)
Instinctif Partners	Tel: +44 (0) 20 7457 2020
Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis	SkinBio@instinctif.com

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit:www.skinbiotherapeutics.com.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Doug Quinn
2	Reason for notification
a.	Position/Status	Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	SkinBioTherapeutics plc
b.	LEI	213800YMQOCB23FX6I06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 1p each ISIN: GB00BF33H870
b.	Nature of the transaction	Sale of shares
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			16p	126,595

d.	Aggregated information - Aggregated Volume - Price	n/a
e.	Date of the transaction	4^th December 2020
f.	Place of the transaction	London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Doug Quinn
2	Reason for notification
a.	Position/Status	Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	SkinBioTherapeutics plc
b.	LEI	213800YMQOCB23FX6I06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 1p each ISIN: GB00BF33H870
b.	Nature of the transaction	Purchase of shares
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			16.02	124,110

d.	Aggregated information - Aggregated Volume - Price	n/a
e.	Date of the transaction	4^th December 2020
f.	Place of the transaction	London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Bernadette Quinn
2	Reason for notification
a.	Position/Status	Spouse of Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	SkinBioTherapeutics plc
b.	LEI	213800YMQOCB23FX6I06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 1p each ISIN: GB00BF33H870
b.	Nature of the transaction	Sale of shares
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			16p	126,595

d.	Aggregated information - Aggregated Volume - Price	n/a
e.	Date of the transaction	4^th December 2020
f.	Place of the transaction	London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Bernadette Quinn
2	Reason for notification
a.	Position/Status	Spouse of Director
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	SkinBioTherapeutics plc
b.	LEI	213800YMQOCB23FX6I06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of 1p each ISIN: GB00BF33H870
b.	Nature of the transaction	Purchase of shares
c.	Price(s) and volume(s)
			Price(s) per share	Volume(s)
			16.02	124,110

d.	Aggregated information - Aggregated Volume - Price	n/a
e.	Date of the transaction	4^th December 2020
f.	Place of the transaction	London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHQZLFBBLLZFBX

Quick facts: SkinBioTherapeutics PLC

Price: -

Market: AIM

Market Cap: -

Follow

View company profile

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE